Drug Search Results
More Filters [+]

Motexafin

Alternative Names: motexafin
Latest Update: 2023-10-04
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: RR Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Motexafin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Non-Small-Cell Lung Cancer|Brain Cancer

Phase 2: Non-Small-Cell Lung Cancer|Glioma|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Adenocarcinoma|Breast Cancer|Brain Cancer|Lymphoma, Non-Hodgkin|Glioblastoma|Melanoma|Brain Stem Cancer|Renal Cell Carcinoma|Gliosarcoma|Multiple Myeloma|Lymphoma, B-Cell

Phase 1: Bronchogenic Carcinoma|Non-Small-Cell Lung Cancer|Head and Neck Cancer|Oropharyngeal Cancer|Leukemia, Plasma Cell|Prostate Cancer|Laryngeal Cancer|Lymphoma|Hypopharyngeal Cancer|Breast Cancer|Breast Diseases|Rectal Diseases|Squamous Cell Carcinoma|Gastrointestinal Cancer|Plasmacytoma|Myelodysplastic-Myeloproliferative Diseases|Prostatic Diseases|Lung Cancer|Intestinal Diseases|Glioma|Colorectal Cancer|Intestinal Cancer|Myeloproliferative Disorders|Multiple Myeloma|Glioblastoma|Oligodendroglioma|Astrocytoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

A6701QIBA

N/A

Unknown status

Prostate Cancer

2022-12-01

NCI-2009-01092

P2

Completed

Glioblastoma|Gliosarcoma

2011-02-16

NCI-2012-01829

P2

Completed

Glioma

2010-04-01

PCYC-0222

P2

Terminated

Chronic Lymphoid Leukemia|Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia

2010-02-01

Recent News Events